Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …

KRAS mutations are the most frequent gain-of-function alterations in patients with lung
adenocarcinoma (LADC) in the Western world. Although they have been identified decades …

Simple Summary Rat sarcoma virus (RAS) GTP-ase proteins represent a key element in
cellular proliferation, growth, and differentiation. Three different isoforms of RAS proteins …

Objectives Concurrent genetic mutations are prevalent in KRAS-mutant non-small cell lung
cancer (NSCLC) and may differentially influence patient outcomes. We sought to …

Mutation in the gene that encodes Kirsten rat sarcoma viral oncogene homolog (KRAS) is
the most common oncogenic driver in advanced non–small cell lung cancer, occurring in …

Background KRAS mutations are found in 20–30% of non-small cell lung cancers (NSCLC)
and were traditionally considered undruggable. KRAS G12C mutation confers sensitivity to …

Objectives Effective therapy for non–small-cell lung cancer (NSCLC) depends on
morphological and genomic classification, with comprehensive screening for guideline …

Lung cancer represents 11.6% of all cancers globally, with more than 2 million new cases
worldwide in 2018. 1 Across all disease stages, non–small-cell lung cancer (NSCLC) has an …

Lung cancer remains the leading cause of cancer-related deaths in both men and women.
However, the discovery of several oncogenic driver mutations and the development of …

Introduction: Mutant KRAS is a genetic driver of multiple cancers that has challenged clinical
anti-cancer therapeutics in the last 3 decades. Neo-antigens encoded by KRAS mutations …